<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02731352</url>
  </required_header>
  <id_info>
    <org_study_id>Ahead-T301</org_study_id>
    <nct_id>NCT02731352</nct_id>
  </id_info>
  <brief_title>Study of Apatinib in Patients With Differentiated Thyroid Cancer</brief_title>
  <official_title>Study of Apatinib in Patients With Local Advanced 131iodine（131I）-Refractory/Resistant Differentiated Thyroid Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of apatinib in locally
      advanced 131I-refractory/resistant differentiated thyroid cancer
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2016</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>An expected average of 8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>An expected average of 8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>Apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apatinib Mesylate Tablets 500 mg qd p.o.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Apatinib Mesylate Tablets 500 mg qd p.o. in differentiated thyroid cancer</description>
    <arm_group_label>Apatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Locally advanced or metastatic differentiated thyroid cancer (papillary, follicular,
             Hurthle cells, poorly differentiated carcinoma). At least one measurable lesion
             (helical CT scan long diameter ≥10mm, meet the requirements of the standard Response
             Evaluation Criteria In Solid Tumors（RESCIST） version 1.1);

          2. Disease progression within 14 months before inclusion;

          3. Subjects must be 131I-refractory / resistant as defined by at least one of the
             following;

               -  Lesions that do not demonstrate iodine uptake on any radioiodine scan

               -  Subjects received a single radioactive iodine therapy within 12 months (≥ 3.7
                  Giga Bequerel（GBq）[≥ 100 millicurie（mCi）]) and target lesion disease progression

               -  Every two radioactive iodine treatment interval &lt;12 months, doses ≥ 3.7 GBq
                  [≥100mCi], disease progress more than 12 months after at least once iodine
                  therapy;

               -  Received a total dose of radioactive iodine therapy ≥ 22.2 GBq (≥ 600 mCi)

          4. main organs function is normal;

          5. Eastern Cooperative Oncology Group（ECOG）Performance Status（PS） :0-2;

          6. An expected survival of ≥ 3 months;

          7. Pregnancy test (serum or urine) has to be performed for woman of childbearing age
             within 7 days before enrolment and the test result must be negative. They shall take
             appropriate methods for contraception during the study until the 8th week post the
             last administration of study drug. For men, (previous surgical sterilization
             accepted), shall agree to take appropriate methods of contraception during the study
             until the 8th week post the last administration of study drug;

          8. Patient has to voluntarily join the study and sign the Informed Consent Form for the
             study;

        Exclusion Criteria:

          1. Other thyroid cancer histological subtypes (such as medullary carcinoma, lymphoma or
             sarcoma);

          2. Received VEGFR inhibitor treatment within 6 months;

          3. Subjects with poor-controlled arterial hypertension (systolic blood pressure&gt; 140 mmHg
             and diastolic blood pressure &gt; 90 mm Hg) despite standard medical management; Coronary
             heart disease greater than ClassII; II-level arrhythmia (including QT interval
             prolongation, for man ≥ 450 ms, for woman ≥ 470 ms) together with Class II cardiac
             dysfunction;

          4. Factors that could have an effect on oral medication (such as inability to swallow,
             chronic diarrhea and intestinal obstruction);

          5. Subjects with high gastrointestinal bleeding risk, including the following conditions:
             local active ulcer lesions with positive fecal occult blood test (++); history of
             black stool, or vomiting blood in the past 3 months;

          6. Abnormal Coagulation (INR&gt;1.5、APTT&gt;1.5 UNL), with tendency of bleed;

          7. Received anti-thyroid cancer chemotherapy treatment (allows the use of low-dose
             chemotherapy with radiation sensitizer) or thalidomide(or derivative) therapy;

          8. Pregnant or lactating women;

          9. Other conditions regimented at investigators' discretion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lin Yansong, MD</last_name>
    <phone>+86-13671116837</phone>
    <email>LinYS@pumch.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Peking</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Yansong, MD</last_name>
      <phone>+86-13671116837</phone>
      <email>LinYS@pumch.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2016</study_first_submitted>
  <study_first_submitted_qc>April 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2016</study_first_posted>
  <last_update_submitted>April 6, 2016</last_update_submitted>
  <last_update_submitted_qc>April 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

